Sichuan Biokin Pharmaceutical (SHA:688506) obtained a commitment letter for a 180 million yuan, three-year loan from Bank of China (HKG:3988, SHA:601988) for its share repurchase program, according to a Saturday filing with the Shanghai bourse.
The drug company plans to repurchase between 100 million yuan and 200 million yuan of shares at 398 yuan apiece.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments